We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

378 hedge funds and large institutions have $8.35B invested in Royalty Pharma in 2024 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 141 increasing their positions, 127 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

222% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $4.19M

11% more repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 127

1.94% more ownership

Funds ownership: 68.15% → 70.09% (+1.9%)

7% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 56

0% more funds holding

Funds holding: 378 → 378 (0)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

10% less capital invested

Capital invested by funds: $9.24B → $8.35B (-$885M)

Holders
378
Holders Change
–
Holders Change %
0%
% of All Funds
5.46%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
60
Increased
141
Reduced
127
Closed
56
Calls
$13.5M
Puts
$4.19M
Net Calls
+$9.31M
Net Calls Change
+$4.69M

Top Buyers

1
Swedbank
Swedbank
Sweden
+$300M
2
BlackRock
BlackRock
New York
+$50.2M
3
BGIM
Brandywine Global Investment Management
Pennsylvania
+$45.4M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$29.5M
5
Invesco
Invesco
Georgia
+$29.5M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$159M
2
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$81.4M
3
Millennium Management
Millennium Management
New York
-$64.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$15.8M
5
CSS
Cubist Systematic Strategies
Connecticut
-$14.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
TI
176
Tidal Investments
Wisconsin
$1.28M -$1.16M -41,778 -46%
Mirae Asset Global ETFs Holdings
177
Mirae Asset Global ETFs Holdings
Hong Kong
$1.27M +$1.34M +48,190 New
Wells Fargo
178
Wells Fargo
California
$1.27M -$60.7K -2,189 -4%
GCP
179
GSA Capital Partners
United Kingdom
$1.27M +$1.11M +39,966 +497%
Macquarie Group
180
Macquarie Group
Australia
$1.23M +$29.4K +1,062 +2%
Fidelity International
181
Fidelity International
Bermuda
$1.23M +$655K +23,638 +103%
NAM
182
Nissay Asset Management
Japan
$1.22M +$48.2K +1,738 +4%
MSFS
183
Main Street Financial Solutions
Pennsylvania
$1.2M +$1.26M +45,470 New
LPL Financial
184
LPL Financial
California
$1.19M +$449K +16,207 +56%
Ameriprise
185
Ameriprise
Minnesota
$1.19M -$3.67M -132,364 -75%
Twin Tree Management
186
Twin Tree Management
Texas
$1.18M -$1.31M -47,128 -51%
TD Asset Management
187
TD Asset Management
Ontario, Canada
$1.16M -$690K -24,880 -36%
Toronto Dominion Bank
188
Toronto Dominion Bank
Ontario, Canada
$1.15M +$60.2K +2,172 +5%
OTPPB
189
Ontario Teachers' Pension Plan Board
Ontario, Canada
$1.12M +$891K +32,142 +313%
Public Employees Retirement Association of Colorado
190
Public Employees Retirement Association of Colorado
Colorado
$1.08M -$72.5K -2,614 -6%
IC
191
IEQ Capital
California
$1.07M -$138K -4,995 -11%
QCM
192
Quantinno Capital Management
New York
$1.04M -$166K -6,001 -13%
PIM
193
Plato Investment Management
Australia
$1.01M – – –
BG
194
BDF Gestion
France
$1.01M +$1.06M +38,181 New
YIH
195
Y-Intercept (HK)
Hong Kong
$1M +$27.6K +995 +3%
Walleye Capital
196
Walleye Capital
New York
$992K +$1.04M +37,635 New
FRM
197
Fox Run Management
Connecticut
$991K +$347K +12,508 +50%
VanEck Associates
198
VanEck Associates
New York
$988K +$54.9K +1,980 +6%
IG
199
ING Group
Netherlands
$963K – – –
Pacer Advisors
200
Pacer Advisors
Pennsylvania
$959K +$375K +13,538 +59%
6 7
8
9 10

RPRX Hedge Fund Activity: Q2 2024 in Review

378 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q2 2024, worth a combined $8.35B — down 9.6% from $9.24B a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new RPRX positions and 56 closed out — a net gain of 4 holders — while 141 added to existing stakes and 127 trimmed.

The largest buyer was Swedbank, opening a new position worth an estimated $300M. The largest seller was Fidelity Investments, cutting an estimated $159M.

  • 378 institutional investors held Royalty Pharma (RPRX) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $8.35B of Royalty Pharma stock for Q2 2024, down 9.6% quarter-over-quarter.
  • 60 funds opened new Royalty Pharma positions in Q2 2024 and 56 closed out, a net change of +4 holders.
  • The largest Royalty Pharma buyer in Q2 2024 was Swedbank, an estimated $300M added.
  • The largest Royalty Pharma seller in Q2 2024 was Fidelity Investments, an estimated $159M sold.

Based on aggregated 13F filings for Q2 2024.